Photo taken from ESMO/LinkedIn
Sep 16, 2024, 10:25
The efficacy benefits of radioisotopes in metastatic castration-resistant prostate cancer – ESMO
ESMO shared on LinkedIn:
“At ESMO24, Late-Breaking Abstracts provide evidence for the efficacy benefits of radioisotopes, radium (Ra)-223 and 177Lu-PNT2002, in metastatic castration-resistant prostate cancer (mCRPC). In the PEACE-3 trial, radiological PFS and OS (interim analysis) were longer with Ra-223 plus enzalutamide versus enzalutamide alone in patients with mCRPC and bone metastases. Initial radiological PFS results appeared encouraging for 177Lu-PNT2002 in PSMA-positive mCRPC after progression.
The final results are eagerly anticipated, according to Karim Fizazi, who provides insights on these findings on the ESMO Daily Reporter.”
Read Further.
Source: ESMO/LinkedIn
More posts featuring ESMO24 on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46